Select Bibliography

Filter by any of these (after searching):

Wagner-Johnston, Nina

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 19 items

Cisplatin-associated neuropathy characteristics compared to those associated with other neurotoxic chemotherapy agents (Alliance A151724)

Albany, Costantine , Dockter, Travis , Wolfe, Eric ... - - Support Care Cancer - 2021

Manuscript - Primary - Primary - Symptom Inter - A151724

Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551

Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother Pharmacol - 2009

Manuscript - Primary - Primary - Lymphoma - CALGB-9551

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J Clin Oncol - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50303

Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017

Abstract - Primary - Primary - Lymphoma - CALGB-50904

Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)

Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50904

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).

LaCasce, Ann S , Dockter, Travis , Ruppert, Amy S , Kostakoglu, Lale ... - - J Clin Oncol - 2022

Manuscript - Primary - Primary - Lymphoma - CALGB-50801

Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)

Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. ... - ASCO - J Clin Oncol - 2014

Abstract - Secondary - Primary - Symptom Inter - N08CB

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)

Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. , Smith, Ellen M.L. ... - - J Clin Oncol - 2015

Manuscript - Secondary - Primary - Symptom Inter - N08CB

Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

Pachman, Deirdre R. , Qin, Rui , Seisler, Drew ... - - Support Care Cancer - 2016

Manuscript - Primary - Primary - Symptom Inter - A151505 , N08C1 , N08CB

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Rosenbaum, Cara A , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Br J Haematol - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50901

A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance)

Ruddy, Kathryn Jean , Pachman, Dierdre , Qin, Rui , Seisler, Drew K. ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Primary - Symptom Inter - A151505 , N08C1 , N08CB

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial

Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020

Manuscript - Secondary - Primary - Lymphoma - CALGB-50303

Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014

Abstract - Secondary - Meta-Analysis - Lymphoma - A051201 , A051202

Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - - Lancet Haematol - 2017

Manuscript - Primary - Primary - Lymphoma - A051201 , A051202

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018

Manuscript - Primary - Primary - Lymphoma - CALGB-50604

5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

Wagner-Johnston, Nina D. , Sloan, Jeff A. , Liu, Heshan ... - - Cancer - 2015

Manuscript - Primary - Long-Term-Followup - Symptom Inter - N03CC

Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.

Zimmerman, Collin Thomas , Atherton, Pamela J. , Pachman, Deirdre R. ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Primary - Symptom Inter - NCT01611155

Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial

Zimmerman, Collin , Atherton, Pam , Pachman, Deirdre , Seisler, Drew ... - MASCC / ISOO - Support Care Cancer - 2015

Abstract - Primary - Primary - Symptom Inter - NCT01611155

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

Zimmerman, Collin , Atherton, Pamela J. , Pachman, Deirdre ... - - Support Care Cancer - 2016

Manuscript - Primary - Primary - Symptom Inter - NCT01611155